Published in Blood and presented at ASH 2024, the LUNA 3 study evaluates the efficacy and safety of rilzabrutinib, an oral Bruton Tyrosine Kinase Inhibitor (BTKi), in patients with previously treated immune thrombocytopenia (ITP). The study showed that rilzabrutinib led to a durable platelet response in 23% of treated patients compared to none in the placebo group. The response was rapid, with a median time of 15 days to first platelet increase. Patients receiving rilzabrutinib experienced a 52% reduction in the need for rescue therapy and reported significant improvements in fatigue and bleeding outcomes. The treatment demonstrated a favorable safety profile, with most adverse events being mild or moderate.
These findings suggest that rilzabrutinib could be a promising new treatment option for patients with persistent or chronic ITP who have had an insufficient response to standard therapies.
A huge thanks to David J. Kuter and the research team for their work in advancing ITP treatment.
For more details, read the full study here: https://lnkd.in/e8cveSrq
